NeuroSense Therapeutics Ltd. Major Shareholders & Ownership History
| Major Shareholder Name | Reporting Date | Shares Held | Market Value | Change in Shares | Ownership |
|---|---|---|---|---|---|
| CLEAR STREET LLC | 11/14/2024 | 65,759 | $10,000 | 10.94% | 0.36% |
| CITADEL ADVISORS LLC | 11/14/2024 | 25,274 | $3,791 | -14.22% | 0.14% |
| WARBERG ASSET MANAGEMENT LLC | 11/06/2024 | 20,201 | $3,432 | -36.88% | 0.11% |
| UBS GROUP AG | 11/14/2024 | 200 | $28 | -66.94% | 0.00% |
NeuroSense Therapeutics Ltd.institutional Ownership - FAQ's
During the previous two years, 5 institutional investors and hedge funds held shares of NeuroSense Therapeutics Ltd.. The most heavily invested institutionals were:
CLEAR STREET LLC: 65,759
CITADEL ADVISORS LLC: 25,274
Warberg Asset Management LLC: 20,201
UBS Group AG: 200
Empery Asset Management, LP: 160,000
0.62% of NeuroSense Therapeutics Ltd. stock is owned by institutional investors.
Institutional investors have bought a total of 271,434 shares in the last 24 months. This purchase volume represents approximately $122,145 in transactions.